8-K: Sera Prognostics' PreTRM Test Reduces Preterm Births

A landmark study published in PREGNANCY demonstrates Sera Prognostics' PreTRM Test significantly reduces earliest preterm births and newborn complications when paired with targeted interventions.

Summary

• The results of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcomes (PRIME) study have been published in the Pregnancy Journal.
• A randomized controlled trial of 5,018 women found that the PreTRM Test, combined with targeted interventions, significantly reduced the risk of preterm birth and improved newborn outcomes.
• Key findings include 56% fewer babies born before 32 weeks and 32% fewer babies born before 35 weeks.
• The study also reported 20% fewer babies admitted to the NICU and a 20% reduction in the odds of neonatal morbidity.
• One NICU day was saved for every 4.2 patients screened using the PreTRM Test and targeted interventions.
• The number needed to screen to prevent a single NICU admission was approximately 39 with the PreTRM Test and targeted interventions, compared to 150 with current standard care.
• The PRIME study excluded women with prior spontaneous preterm birth or premature cervical shortening, highlighting the test's value for patients at otherwise low overall risk.
• The study included a diverse population with no significant differences in patient demographics between the control and treatment arms.

Sentiment

Score: 9

Explanation: The filing announces highly positive clinical trial results for the company's flagship product, demonstrating significant efficacy and cost-effectiveness in addressing a major public health issue. This strong validation is a substantial positive for the company's commercial prospects and market position.

Positives

• Significant reduction in earliest preterm births: 56% fewer babies born before 32 weeks and 32% fewer babies born before 35 weeks.
• Improved neonatal outcomes, including 20% fewer NICU admissions and a 20% reduction in the odds of neonatal morbidity.
• Demonstrated cost-efficiency by saving one NICU day for every 4.2 patients screened.
• The PreTRM Test is a first-of-its-kind, personalized, non-invasive blood test for predicting spontaneous preterm birth in asymptomatic singleton pregnancies.
• The findings reinforce strong results from the previous AVERT PRETERM Trial, building a robust body of clinical evidence.
• Offers a solution to improve outcomes for historically disadvantaged groups disproportionately impacted by birth complications.
• Management sees a significant opportunity to transform maternal and neonatal health outcomes, setting a new commercial and clinical standard.

Risks

• Net losses, cash generation, and the potential need to raise more capital.
• Revenues from the PreTRM Test representing substantially all Company revenues to date.
• The need for broad scientific and market acceptance of the PreTRM Test.
• A concentrated number of material customers.
• Ability to introduce new products.
• Potential competition.
• Reliance on a proprietary biobank.
• Reliance on critical suppliers.
• The COVID-19 pandemic and its potential lingering impact on operations, as well as the business or operations of third parties.
• Estimates of total addressable market opportunity and forecasts of market growth may be inaccurate.
• Uncertainty regarding potential third-party payer coverage and reimbursement.
• New reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes.
• Changes in FDA regulation of laboratory-developed tests.
• The intellectual property rights protecting tests and market position.
• Other factors discussed under the heading 'Risk Factors' in Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Sera Prognostics is committed to building a robust, differentiated body of clinical evidence for the PreTRM test-and-treat strategy, driving education, awareness, and equitable access to prenatal care. The company sees a significant opportunity to transform maternal and neonatal health outcomes, aiming to set a new commercial and clinical standard that delivers measurable value for patients, providers, and health systems. Management will discuss the full PRIME study results during a Jefferies fireside chat.

Management Comments

• Dr. Brian Iriye, principal investigator for the PRIME study, stated: 'Today, many women who ultimately deliver prematurely would be considered low risk by traditional criteria, and that gap is not acceptable. By quantifying a woman's biologic risk early in pregnancy, the PreTRM Test allows us to move beyond guesswork and implement a straightforward, low-burden, evidence-based care plan that supports her, protects her baby, and improves outcomes for the families we serve—while reducing the downstream cost and complications of being born too soon.'
• Zhenya Lindgardt, President and CEO of Sera Prognostics, commented: 'These findings not only reinforce the strong results from the AVERT PRETERM Trial but also enhance our ability to build a robust, differentiated body of clinical evidence for the PreTRM test-and-treat strategy... With preterm birth still impacting 1 in 10 infants in the U.S., our commitment extends beyond innovative technologies like the PreTRM Test to driving education, awareness, and equitable access to prenatal care. Looking ahead, we see a significant opportunity to transform maternal and neonatal health outcomes, setting a new commercial and clinical standard that delivers measurable value for patients, providers, and health systems.'

Industry Context

Preterm birth is the leading cause of illness and death in newborns, affecting more than one in ten infants in the U.S. annually with significant long-term health and economic consequences. The PreTRM Test addresses a critical unmet need by providing an early, accurate, and individualized risk prediction for spontaneous preterm birth, particularly for asymptomatic women not identified by traditional screening methods. This advancement positions Sera Prognostics to significantly impact maternal and neonatal health outcomes, potentially reducing healthcare burdens and improving care for historically disadvantaged populations.

Comparison to Industry Standards

• The PreTRM Test and targeted interventions demonstrated a more effective and efficient strategy in reducing NICU admissions and length of stay than current standard care.
• The number needed to screen to prevent a single NICU admission was approximately 39 with the PreTRM Test and targeted interventions, significantly better than the 150 required when using current standard care.
• Only about 4 women need to be screened with PreTRM and treated to prevent one day in the NICU, indicating superior efficiency compared to existing methods.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong clinical validation, potential for increased market adoption, and improved financial performance.
• Patients (pregnant women): Significant improvement in health outcomes, reduced risk of preterm birth, and fewer neonatal complications.
• Healthcare Providers: Enhanced ability to identify and manage preterm birth risk, supported by evidence-based care plans and improved diagnostic tools.
• Health Systems: Potential for reduced downstream costs associated with preterm birth complications and NICU stays due to more effective prevention.
• Newborns: Direct benefit from fewer health complications and reduced admissions to the NICU.

Next Steps

• Sera Prognostics management will participate in a Jefferies fireside chat on January 9, 2026, at 8:30 a.m. ET to discuss the full PRIME study results.
• Continue to build a robust, differentiated body of clinical evidence for the PreTRM test-and-treat strategy.
• Drive education, awareness, and equitable access to prenatal care.
• Work towards transforming maternal and neonatal health outcomes and setting a new commercial and clinical standard.

Key Dates

Recommendation

The announcement of landmark clinical trial results for the PreTRM Test provides compelling evidence of its efficacy and cost-effectiveness in reducing preterm births and improving neonatal outcomes. This strong validation significantly de-risks the company's core product, suggesting a substantial increase in its market potential, likely leading to broader adoption and favorable reimbursement. Such a positive development is a strong indicator for future revenue growth and market leadership in precision pregnancy care, making the stock a strong buy for investors.

Keywords

Preterm birth, PreTRM Test, Sera Prognostics, PRIME study, neonatal outcomes, maternal health, blood test, pregnancy, diagnostics, SEC filing, 8-K